aggregatereportingpvkatalysthls-170327013344.pdf

Aggregate Reporting
3/27/2017
Katalyst HealthCares & Life Sciences
Pharmacovigilance/Drug Safety

• Introduction
• Type of safety reports
• Basic terminologies
• General principles
• Submission timelines
3/27/2017

Aggregate Reporting?
• To provide a concise summary of safety information, and an evaluation of the benefit-
risk profile of the medicinal product to identify safety information that would require:
– Further investigation of the product
– Changes to the medicinal product label
• Aggregate safety reports play a key role in the safety assessment of medicinal product
• The exact type of report that is required varies by country and regulatory authorities
3/27/2017

Sources of safety information
• Spontaneous reports
• Clinical trials
• Literature
• Observational studies
• Non-clinical studies
• Patient support programs
• Licensing partners
• Competent authorities
3/27/2017

Type of reports
• Development Safety Update Report (DSUR)
• Periodic Adverse Drug Experience Report (PADER)
• Periodic Safety Update Report (PSUR)
• Periodic Benefit-Risk Evaluation report (PBRER)
3/27/2017

Basic Terminologies
• International Birth Date/DIBD
• Data Lock point
• Reporting interval/Cumulative period
• Company Core Data Sheet (CCDS)
• Company Core Safety Information (CCSI)
• Line listings
• Summary of tabulations
• Pharmacovigilance Risk Assessment Committee
• Safety concerns
– Identified Risk
– Potential Risk
– Missing Information
3/27/2017

General principles
• Single DSUR/PBRER for an active substance
• PBRERs for fixed-dose combination product
• Products manufactured or marketed by more than one company
• Reference information
• Benefit-Risk evaluation
3/27/2017

PBRER
Submission timelines:
• PSURs covering intervals up to 12 months: with in 70 calendar days from DLP
• PSURs covering intervals in excess of 12 months: within 90 calendar days from DLP
• Adhoc PSURs: within 90 calendar days of the data lock point
Frequency of submission:
• Every 6 months for first two years
• Annually for the next two years
• Every 3 years thereafter
• Every five years
3/27/2017

Objectives
• To present a comprehensive, concise, and critical analysis of new or emerging
information on the risks of the medicinal product, and on its benefit in approved
indications, to enable an appraisal of the product’s overall benefit-risk profile
– Summarising relevant new safety information that could have an impact on the
benefit-risk profile of the medicinal product
– Summarising any important new efficacy/effectiveness information that has
become available during the reporting interval
– Examining whether the information obtained by the MAH during the reporting
interval is in accord with previous knowledge of the medicinal product’s benefit
and risk profile
– Where important new safety information has emerged, conducting an integrated
benefit-risk evaluation for approved indications
3/27/2017

Title page
• Medicinal product (s) name along with active substance
• Formulation and strength
• International Birth Date
• Reporting interval
• Date of the report
• MAH details
• Signature of the responsible person
3/27/2017

Executive summary
• It provides a concise summary of the content and the most important information of
the PSUR.
• Introduction
• Therapeutic class, MOA, indication(s), formulation(S), dose, and route of
administration
• Estimated cumulative clinical trials exposure
• Estimated interval and cumulative exposure from post marketing experience
• Number of countries in which the medicinal product is authorized
3/27/2017

• Summary of the overall benefit-risk analysis evaluation
• Actions taken and proposed for safety reasons
• Conclusion
3/27/2017

Introduction
• Brief introduction to the product, PSUR standalone statement and
reporting interval information about previous PSUR
• IBD and reporting interval
• Product information: Therapeutic class, MOA, authorised indications,
formulation, dose and route of administration
• Information on other PSURs that submitted during the reporting
interval
3/27/2017

Section 2: Worldwide marketing authorization status
• Overview to the product information
– Date of the first authorization
– Country of authorization
– Indication
– Authorised doses
– Available strengths
This information usually appended in the report
3/27/2017

Section 3: Actions taken in the reporting interval for safety
reasons
• This section should describe significant actions related to safety that
have been taken during the reporting interval.
• Related to Investigational uses or marketing experience by the MAH,
sponsors clinical trials or competent authorities
– A significant influence on the benefit-risk profile of the approved
medicinal product
– An impact on the conduct of a specific clinical trials
Reasons for each action should be provided, if known, and additional
relevant information should be provided when appropriate.
3/27/2017

Actions related to investigational drugs:
• Suspension or early termination of an ongoing clinical trial because of
any safety findings or lack of efficacy
• Recall of investigational drug or comparator
• Failure to obtain marketing approval for a tested indication
• Protocol modifications due to safety or efficacy concerns
• Changes to the informed consent document relating to safety concerns
• Restrictions in study population or indications
3/27/2017

Actions related to marketed drugs
• Failure to obtain or apply for a marketing approval renewal
• Withdrawal or suspension of a marketing approval
• Suspension of supply by the MAH
• Significant safety related changes in the labeling documents, including
restrictions on use or population treated
• Communication to healthcare professionals
• New post-marketing study requirements if imposed by regulators
3/27/2017

Section 4: Changes to reference safety information
• Information on significant changes made to the reference information
during the reporting interval
– Contraindications
– Warnings and precautions
– Adverse drug reactions
– Interactions
– Pregnancy and lactation
– Overdose
3/27/2017

Section 5: Estimated exposure and use patterns
• This section should provide estimates of the size and nature of the
population exposed to the medicinal product
• Brief descriptions of the methods used to estimate the patient
exposure
• Consistent methods for calculating patient exposure should be used
across PBRERs
• If a change in the method is appropriate, the same need to provided
with a justification
3/27/2017

Section 5.1: Cumulative subject exposure in clinical trials
• Cumulative numbers of subjects from ongoing and completed clinical
trials exposed to the investigational medicinal product, placebo, and/or
active comparator(s) since the DIBD
• It is recognized that for older products, precise data might not be
available.
• If available, more detailed cumulative subject exposure in clinical trials
– Age
– Sex
– Racial/ethnic group
3/27/2017

Section 5.2: Cumulative and interval patient exposure from
marketing experience
• 5.2.1 – Cumulative and interval exposure
– Separate estimations should be provided for interval exposure
– Current reporting interval exposure
– Previous reporting interval exposure
– Cumulative exposure
– Daily defined dose concept will be used to calculate the exposure
– Data should be presented by indication, sex, age, dose, formulation, and
region where applicable
Patient exposure = Total exposure in mg/DDD*treatment days/years
3/27/2017

• 5.2.2: Use in special populations
– Pediatric population
– Elderly population
– Pregnant or lactating women
– Patient with renal impairment
– Patients with hepatic impairment
– Patients with other relevant co-morbidity
• 5.2.3: Other post-approval use
– Off-label use
– Drug abuse
– Drug misuse
3/27/2017

Section 6: Data in summary tabulations
• 6.1: Reference information
– Specifies the version of the coding dictionary used for analysis of adverse
reactions
• 6.2: Cumulative summary tabulations of serious adverse events from clinical
trials
– Provides a cumulative summary tabulation of SAEs reported in the MAH’s clinical
trials, from the DIBD.
– The tabulation(s) should be organized by system organ class (SOC), for the
investigational drug, as well as for the comparator arm(s) (active comparators,
placebo) used in the clinical development programme.
3/27/2017

• 6.3: Cumulative and interval summary tabulations from post-
marketing data sources
– Cumulative and interval summary tabulations of adverse reactions, from the IBD
to the DLP of the current PBRER.
– Serious and non-serious adverse drug reactions from spontaneous ICSRs,
including reports from healthcare professionals, consumers, scientific literature,
and regulatory authorities
– Serious adverse reactions from non-interventional studies
3/27/2017

3/27/2017

Section 7: Summaries of significant safety findings from clinical
trials during the reporting interval
• This section of the PBRER should provide a brief summary of clinically
important emerging efficacy/effectiveness and safety findings obtained from
the MAH’s sponsored clinical trials that became available during the reporting
interval of the report
• The safety signals arising from clinical trial sources should be tabulated in
Section 15 of the PBRER
• New information in relation to any previously known potential or identified
risks and not considered to constitute a newly identified signal should be
evaluated and characterized in Sections 16.3 and 16.4, respectively
• Findings from clinical trials not sponsored by the MAH should be described in
the relevant sections of the PBRER.
3/27/2017

• The following information should be presented for each trial:
– Study ID (e.g., protocol number or other identifier)
– Study title (abbreviated study title, if applicable);
– Study type (e.g., randomized clinical trial, cohort study, case-control study);
– Population studied (including country and other relevant population descriptors,
e.g., paediatric population or trial subjects with impaired renal function);
– Study start (as defined by the MAH) and projected completion dates;
– Status: Ongoing or Completed
3/27/2017

• Section 7.1: Completed clinical trials
– Brief summary of clinically important emerging efficacy and safety findings
obtained from clinical trials completed during the reporting interval
• Section 7.2: Ongoing clinical trials
– Clinically important information (safety and efficacy) that has arisen from ongoing
clinical trials
• Section 7.3: Long-term follow-up
– Provides information from long-term follow-up of subjects from clinical trials of
investigational drugs, particularly advanced therapy products
3/27/2017

• Section 7.4: Other therapeutic use of medicinal product
– Includes clinically important safety information from other programmes
conducted by the MAH that follow a specific protocol
– E.g. : Compassionate use programmes
• Section 7.5: New safety data related to fixed combination therapies
– If the product that is the subject of a PBRER is also approved or under
development as a component of a fixed combination product or a multi-drug
regimen, this section should summarize important safety findings from use of the
combination therapy.
– If this PBRER is for a fixed combination product, this section should summarize
important safety information arising from the individual components.
3/27/2017

Section 8: Findings from non-interventional studies
• This section should summarise relevant safety information or
information with potential impact on the benefit or risk evaluations,
from MAH-sponsored non-interventional studies that became available
during the reporting interval
– Observational studies
– Epidemiological studies,
– Patient registries programmes
3/27/2017

Section 9: Information from other clinical trials
and sources
9.1: Other clinical trials:
• This section should summarise information accessible to the MAH with
reasonable and appropriate effort from any other clinical trials
• Safety information provided by co-development partners
9.2: Medication errors
• This subsection should summarise relevant information on patterns of
medication errors and potential medication errors, even when not
associated with adverse outcomes
3/27/2017

3/27/2017
Thank You
&
Questions
3/27/20
Contact:
Katalyst Healthcare’s & Life Sciences
South Plainfield, NJ, USA 07080.
E-Mail: info@KatalystHLS.com

aggregatereportingpvkatalysthls-170327013344.pdf

Recommended

Recommended

More Related Content

Similar to aggregatereportingpvkatalysthls-170327013344.pdf

Similar to aggregatereportingpvkatalysthls-170327013344.pdf (20)

More from dabloosaha

More from dabloosaha (8)

Recently uploaded

Recently uploaded (20)

aggregatereportingpvkatalysthls-170327013344.pdf